Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com - Evercore ISI has raised its price target on West Pharmaceutical (NYSE:WST) to $350 from $275 while maintaining an Outperform rating on the stock. The $20 billion market cap company, currently trading at $277.82, has demonstrated strong financial health according to InvestingPro analysis.
The research firm cited West Pharmaceutical’s strong performance "across the board amid a choppy macro environment" as a key factor in its decision to increase the price target.
Evercore ISI noted that the company is "setting the table for a strong second half and 2026," suggesting confidence in West Pharmaceutical’s near and medium-term outlook.
The new $350 price target implies approximately 44 times the company’s projected 2026 price-to-earnings ratio and about 30 times its expected EBITDA.
West Pharmaceutical, which specializes in injectable drug administration and packaging solutions, continues to receive positive analyst sentiment despite broader market challenges.
In other recent news, West Pharmaceutical Services Inc . announced its financial results for the second quarter of 2025, which exceeded analyst expectations. The company reported earnings per share (EPS) of $1.84, surpassing the anticipated $1.51, representing a surprise of 21.85%. Additionally, West Pharmaceutical Services achieved revenue of $766.5 million, outperforming the forecasted $725.26 million by 5.69%. These results indicate stronger-than-expected performance for the quarter. The company’s stock experienced a notable increase in premarket trading following the announcement, reflecting positive investor sentiment. This development highlights the company’s ability to exceed market predictions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.